Pharma Focus Asia

An innovative drug for Alzheimer's disease from China at the end of Phase 3 clinical trials

Friday, July 20, 2018

Shanghai Green Valley Pharmaceutical Co., Ltd  today announced that Phase 3 trials for Sodium Oligomannurarate (GV-971) capsules used in mild to medium-sized cases Alzheimer's disease reached the first endpoint.

Randomized, double-blind clinical trials with placebo in China aimed to assess the safety and efficacy of GB-971, an oligosaccharide drug with multilateral targeting. Patients with mild to moderate Alzheimer's disease (MMSE score 11 to 26) were included in the study. Regarding treatment, patients received 450 mg of GV-971 orally twice daily for 36 weeks. The first endpoint showed a better change in the cognitive scale of Alzheimer's disease (the so-called ADAS-cog) after 36 weeks of taking GV-971 compared to the placebo control group. The data showed that substance GV-971 contributed to a significant improvement in cognitive function problems. Regarding side effects,

Alzheimer's disease is a chronic neurodegenerative disease characterized by progressive loss of cognitive function. According to Alzheimer's Disease International, around 48 million patients suffer from Alzheimer's disease worldwide, and this number is expected to rise to 130 million by 2050 due to the aging population.

Later this year, Green Valley plans to apply for permission to promote GV-971 in the treatment of mild to moderate Alzheimer's cases issued by the Chinese Office for Drug Administration.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024